Alpha Cognition Inc. (OTC:ACOGF – Get Rating) – Investment analysts at Zacks Small Cap raised their FY2023 earnings estimates for Alpha Cognition in a research report issued on Wednesday, March 15th. Zacks Small Cap analyst J. Vandermosten now expects that the company will earn ($0.09) per share for the year, up from their prior forecast of ($0.17). The consensus estimate for Alpha Cognition’s current full-year earnings is ($0.09) per share.
Separately, Raymond James downgraded shares of Alpha Cognition from an “outperform” rating to a “market perform” rating in a research report on Friday, February 10th.
Alpha Cognition Trading Down 12.8 %
Alpha Cognition Company Profile
Alpha Cognition Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). It develops ALPHA-1062, an acetylcholine esterase inhibitor for the treatment of dementia of the Alzheimer's type and mild traumatic brain injury; and ALPHA-0602, a gene therapy for the treatment of ALS.
Further Reading
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Alpha Cognition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Cognition and related companies with MarketBeat.com's FREE daily email newsletter.